Plasma Metabolomic Profiling of Individuals Susceptible to High Altitude through Gas Chromatograph- mass Spectrometry

Chi Wang  
PLAGH: Chinese PLA General Hospital

Hui Jiang  
Chinese PLA General Hospital

Jingwen Chen  
Chinese PLA General Hospital

Jinyan Duan  
Chinese PLA General Hospital

Chengbin Wang  
( wangcb301301@163.com )  
Chinese PLA General Hospital

Research

Keywords: metabolomics, acute mountain sickness, gas chromatography-mass spectrometry

Posted Date: December 1st, 2020

DOI: https://doi.org/10.21203/rs.3.rs-114628/v1

License: ☐ ☑ This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Objective** We aimed to characterize metabolic alterations of people ascending to high altitude and susceptible to acute mountain sickness (AMS).

**Methods** Peripheral blood samples were collected from 36 healthy volunteers on the 3rd day ascending to high altitude (4300m). AMS status was assessed using the Lake Louise Questionnaire. Plasma samples were characterized by gas chromatography-mass spectrometry (GC-MS) and principal component analysis (PCA) was used to discriminate the metabolite changes between sea level and high altitude status and between AMS group and non-AMS group.

**Results** High altitude hypobaric hypoxia caused significant and comprehensive metabolic changes in plasma, including 18 metabolites between sea level and high altitude, 6 metabolites between AMS group and non-AMS group. By using MetaboAnalyst 3.0, several key metabolic pathways were found to be involved, including cysteine and methionine metabolism, alanine, aspartate and glutamate metabolism.

**Conclusion** The GC-MS profiling was a useful approach to analyze metabolites variances and provides potential targets for further investigation to understand the pathophysiological mechanism of hypobaric hypoxia and susceptibility to high altitude.

Introduction

In high-altitude plateau environments, the main physiological challenge is hypoxia. Upon rapid ascent to altitude above 3000 m, non-acclimatized healthy individuals are highly prone to contracting acute mountain sickness (AMS), high-altitude cerebral edema (HACE), or high-altitude pulmonary edema (HAPE) due to hypoxia. With increasing number of people entering the plateau, AMS has become a health-related issue not only impairs human activity but also enhances the costs of health care. AMS is a transient condition and the routine diagnosis method is Lake Louise Score, which evaluates symptoms such as headache, weakness, sleeplessness, etc. Despite the detailed clinical characterization, the pathophysiology of AMS remains unclear and this scoring system may not be suitable for early diagnosis, thus leading to the delay of treatment and worsening of disease. Therefore, accurate and prompt biomarkers are urgently required to identify people who are sensitive to hypoxia at high altitude, but none of which are currently available.

Metabolomics platform is a newly developed tool for system biology, which can identify and quantify all small molecular metabolites within a biological system. Metabolic profiling is used to define metabolic changes in response to genetic differences, environmental influences and disease or drug perturbations at global scale. Equipped with advanced high throughput platforms, bio statistical analysis software and bioinformatics tool, metabolomics has become an irreplaceable approach to obtain and compare the full complement of metabolites in tissue samples between groups to discover slight changes to external stimulation. It has developed rapidly and become an effective tool for disease diagnosis, biomarker...
screening, and characterization of biological pathways. Nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) are currently prevailing techniques used to explore metabolic changes in urine or plasma. Single analytical approach of NMR or LC-MS may not be able to provide full coverage of even the simplest metabolites with diverse concentration and mass range. GC-MS, on the other hand, has been increasingly applied in laboratories because of its easier metabolites identification approach based on by comparing their mass spectrum and retention index with authentic reference standards or commercial libraries. So far, studies focusing on using “omics” have provided large amount of background information about high-altitude illness, among which metabolomics is a newly developed one. Johnson CH came up with the idea that proteomic variation can cause metabolomics variation and this furthers the use of metabolomics in the research of altitude illness.

Since some individuals are more susceptible to high altitude diseases than others, the incidence of high-altitude diseases is variable among different population. Given that the pathophysiology of the susceptibility of AMS remains unresolved, the broader view provided by metabolomics may provide novel insights into the etiology of AMS and identify novel biomarkers for the prompt diagnosis of the condition. Herein, a metabolomics method based on GC-MS and random forest (RF) models were applied to analyze the serum samples of people rapidly ascending to high altitude and to comprehensively investigate the metabolic profiling changes of AMS.

**Materials And Methods**

**Subject recruitment**

Subjects recruited for analysis were male health volunteers living at sea level. Inclusion criteria were as follows: absence of acute infection during the past 6 months, absence of chronic inflammatory diseases, with no organic diseases, with the age >18 years, and >6 months stay at sea level. Volunteers were excluded if they had any health problems, abnormal complete blood count, chemistry panel or liver function results or those who had been to high altitude during the past 6 months. All subjects’ general health status eligibility were assessed and determined prior to participation including medical history, physical check, and standard blood and urine analysis. They all ascended by train to Golmud district (altitude 4300m) in Qinghai, China. All subjects signed informed consent to all the risks involved in this study and they did not receive any preventative drugs before or during ascending to high altitude. Our study has been approved by the Ethics Committee of the Chinese PLA General Hospital.

**AMS assessment and physiological examination**

To evaluate AMS status, subjects recruited for this clinical study completed the self-reported questionnaire on the 3rd day arriving at high altitude. The diagnosis of AMS was based on the Lake Louise Score (LLS) system. Five symptoms including headache, gastrointestinal symptoms,
fatigue/weakness, dizziness/light-headedness, and difficulty in sleeping were assessed. Participants scored the severity of each symptom from 0 (no symptom) to 3 (maximal severity). Individuals whose total score exceeded 3 points and were accompanied with headache were diagnosed as AMS. And subjects whose LLS scores were lower than 3 points were selected as control group. Blood pressure, heart rate and oxygen saturation were also measured both at sea level and on the 3rd morning after ascending to high altitude. Arm blood pressure (BP) monitor (KD-5903; Andon Health Co., Ltd. Tianjin) was used to determine brachial artery BP of each volunteer for three times and average value was acquired. SpO2 of fingertip and pulse rate were measured with pulse oximeter (YX301; Yuwell Medical Equipment & Supply Co., Ltd., Jiangsu), both of which were performed on right index fingers in the morning before breakfast.

**Blood sample collection, conservation and preparation**

Venous blood (4ml) was collected in EDTA-K$_2$ tubes from each overnight fasting individual in the morning at sea level and on the third day after ascending to Golmud. Plasma was separated through centrifugation at 3000rpm for 5 minutes, stored at -20°C and then transported to Beijing and stored at -80°C until further analysis.

The preprocessing procedures before GC-MS analysis included deproteinization, drying and chemically derivatization. Plasma was thawed at 4°C for 20 min and centrifuged for 15 min (15,800 rpm, 4°C). To the 100 μl supernatant, 400 μl methanol was added for deproteinization and centrifuged for another 15 min. Then ribitol was added as internal standards at the concentration of 1 mg/ml and mixed on a vortex for 15s. The above samples were put on ice in ventilated cabinet. After methanol was volatilized, they were put at -70°C for over 4h until dried. One microliter of each supernatant was then transferred to the sample for the following GC-MS procures. The remaining was combined to generate a pooled quality control (QC) sample. Then dried samples were derivatized using freshly prepared methoxylamine/pyridine (50 mg/ml) and incubated for 90min (30°C). Next, 80 μl of N-methyl-N- (trimethylsilyl) trifluoroacetamide (MSTFA) with 1% trimethylchlorosilane (TMCS) was added to the samples which were then incubated for 2h at 37°C.

**Gas chromatography-mass spectrometry conditions**

Samples were analyzed on the Agilent 7890A gas chromatograph with a 5975C time-of-flight mass spectrometer (Agilent Technologies, America) that equipped with an auto-sampler 7693 and electron ionization (EI) source. A 30m×0.25mm×0.25 μm deactivated fused silica capillary column (Agilent Technologies) was used for the GC-MS analysis. The primary temperature was maintained at 60°C for 4 min, programmed to 180°C at a rate of 10°C/ min, and slowed down to the rate of 3°C/min to 260°C, then rise the rate again at 10°C/min until 300°C and held for 10 min. The temperatures of the front injection port, interface and ion source were set at 270°C, 280°C and 230°C, respectively. Helium was used as the carrier gas with a flow rate of 1.0 ml/min. One microliter of sample was injected in the 10:1 split mode.
The MS quadrupole temperature was 150°C. The mass spectrometer was operated under electron impact (EI) mode at ionization energy of 70 eV, with a scanning extent of 85-500m/z and was set for five scans per second.

**Quality control**

A quality control (QC) sample theoretically identical to the biological samples, with a metabolic and sample matrix composition similar to those of the biological samples under study, is used in our study. A pooled QC strategy deriving from all the subject population was applied. Equal quantities were taken from every sample and mixed together as the QC sample. The serum samples and the QC samples were labeled. Before the experimental samples were injected, QC samples were used to equilibrate the GC-MS. All the samples were then analyzed in GC-MS at random in order to avoid the run order effect.

**Identification and quantification of metabolites**

Data from GC-MS was processed by GC/MSD Chem Station Software (Agilent) for auto-acquisition of GC total ion chromatograms (TICs) and fragmentation patterns. Then all transformed data was processed sequentially with the assistance of Qualitative Analysis B.04. Since there was a serious of split molecular ions for each compound fragmentation pattern, the National Institute of Standards and Technology (NIST) mass spectra library by the Chem Station Software was used to make the comparison. The standard mass chromatogram from NIST, which includes the mass charge ratios and the abundance of compound fragmentation, can search the following parameters including the compound's name, constitutional formula, retention time, relative molecular weight etc. For each peak, the software generated a list of similarities with those within the NIST library. Peaks with matching factor over 85% were assigned compound names, those having < 85% similarity were listed as unknown metabolites. Internal standard was used to obtain the relative quantification of these compounds. The results were exported in .cef files, which included the above parameters.

**Multivariate data processing**

Feature extraction and pre-processing of the obtained data were performed using R software, and then normalized and edited into two-dimensional data matrix by Excel 2010 software. Parameters including Retention time (RT), Mass-to-charge ratio (MZ), Observations (samples) and peak intensity were collected. Multiple variables statistical procedures of principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) were applied to observe the plasma profiles from different groups using SIMCA-P 13.0 software (Umetrics AB, Umea, Sweden). The quality of the models was evaluated by the relevant $R^2_X$ (explainable index) and $Q^2$ (predictable index). PCA models were regarded as valid only if $R^2 (X) > 0.4$. PLS-DA models were regarded as valid only if $Q^2 > 0.4$. All of the data from the differentially expressed compounds were used in calculating PCA models (an unsupervised
statistical procedure that uses orthogonal transformation to convert a set of observations of possibly correlated variables into a set of values of linearly uncorrelated variables called principal components).

Significantly characteristic differential metabolites or metabolic features between sea level and high altitude groups, AMS and non-AMS groups were screened using the OPLS-DA model. The Paired t-test was selected to measure the significance of each metabolite in separating sea level from high altitude group and AMS from non-AMS groups. Fold change is calculated through the Logarithmic value (2 as the base value) of ratio between AMS group and non-AMS group. A positive value indicates a relatively higher concentration present in AMS group, whereas a negative value indicates a relatively higher concentration in non-AMS group. The differences were considered significant when p <0.05.

Commercial databases, including the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/) databases were used to search for metabolite pathways. More detailed analysis of the relevant pathways and networks of AMS is performed by MetaboAnalyst 3.0, which revealed that these differential metabolites are important for the organism response to high altitude or AMS and are responsible for multiple pathways. MetaboAnalyst is a free, web-based tool that combines results from a powerful pathway enrichment analysis concerning the conditions under study 14.

Results

General characteristics of enrolled subjects

In our current study, 36 volunteers met the inclusion and exclusion criteria and thus were included. Based on the Lake Louise Score System, 17 of the included subjects were divided into AMS group while the rest 19 were defined as non-AMS. The clinical characteristics of these subjects were illustrated in Table 1. On the third day after arriving at high altitude, the physiological responses could be reflected through significantly increased heart rate (66.3 ± 5.6 at sea level, 81.3 ± 11.2 for AMS group and 82.3 ± 8.2 for non-AMS group) and blood pressure (75.3 ± 5.3 mmHg at sea level, 85.4 ± 8.9 mmHg for AMS group and 82.4 ± 7.2 mmHg for non-AMS group) and significantly decreased oxygen saturation (98.7 ± 1.8% at sea level, 86.9 ± 6.7% for AMS group and 89.3 ± 6.5% for non-AMS group). None of these subjects progressed to the more severely fatal forms of high altitude pulmonary edema or high altitude cerebral edema.
Table 1
General physiological characteristics of enrolled subjects (Data are presented as mean ± SD)

| Variables               | Sea level | High altitude (3rd day) | AMS | Non-AMS |
|-------------------------|-----------|-------------------------|-----|---------|
| Altitude                | 20–60 m   | 4300 m                  | 4300 m |
| Heart rate (bpm)        | 66.3 ± 5.6| 81.3 ± 11.2*            | 82.3 ± 8.2* |
| Oxygen saturation (%)   | 98.7 ± 1.8| 86.9 ± 6.7*             | 89.3 ± 6.5* |
| Blood pressure (mmHg)   |           |                         |     |         |
| Diastolic BP            | 75.3 ± 5.3| 85.4 ± 8.9*             | 82.4 ± 7.2* |
| Systolic BP             | 113.6 ± 7.8| 120.3 ± 8.6*             | 117.6 ± 10.3* |
| Lake Louise Score       | 0         | 4.2 ± 0.8*              | 1.9 ± 0.6 |

* p < 0.05, compared with sea level status.

Multivariate statistical analysis of metabolites

1892 features were collected in this experiment. To determine whether the metabolite fingerprints in plasma differed between non-AMS and AMS subjects, subjects at sea level and high altitude, we first evaluated separation using unsupervised PCA and supervised OPLS-DA. The obvious separation was achieved between sea level group and high altitude group (Fig. 1A). For the two groups, there were 17 principal components. The PCA model score plots were characterized by the following parameters: $R^2_X = 0.894$ and $Q^2 = 0.682$. Based on the OPLS-DA model (Fig. 1B), sea level group and high altitude group were discriminated with an $R^2_X = 0.508$, $R^2_Y = 0.78$, $Q^2 = 0.496$. The OPLS- DA model is regarded as valid due to $Q^2 > 0.4$.

Comparison of metabolites between AMS group and non-AMS group

The variable importance in the projection (VIP) parameter reflecting the importance of variables was applied to filter the important metabolites in the model. Variables with VIP values higher than 1 were selected in this study and variables without support of its confidence interval were rejected. The qualitative analysis of differential metabolites is based on the retention time (RT), m/z and the matched metabolites were researched in the NIST library. 18 variables were identified by comparison between the sea level group and high altitude group (Table 2), among whichalanine and cyclohexasiloxane significantly increased in high altitude group, while other 16 metabolites decreased compared with sea level group. In addition, 6 variables were identified between AMS group and non-AMS group, among
which uric acid decreased in AMS group, while Propanoic acid, silane, talose, D-glucose and 1-Deoxyglucose increased compared with non-AMS group (Table 3).

| No. | ID  | Metabolite          | VIP   | m/z    | RT    | P value | Log₂ Fold change (SL/HA) |
|-----|-----|---------------------|-------|--------|-------|---------|--------------------------|
| 1   | 25  | Propanoic acid      | 1.607 | 43.0930| 9.71  | 0.013   | 0.585                    |
| 2   | 132 | Urea                | 1.012 | 66.0003| 12.38 | 0.026   | 0.229                    |
| 3   | 1089| Pentasiloxane       | 1.192 | 249.9649| 11.23 | 0.021   | 0.796                    |
| 4   | 931 | L-Tyrosine          | 1.054 | 219.0911| 9.72  | 0.004   | 0.415                    |
| 5   | 1508| Phosphoric acid     | 1.142 | 358.0740| 48.35 | 0.002   | 0.419                    |
| 6   | 862 | D-Glucose           | 1.375 | 206.1377| 24.54 | 0.012   | 0.114                    |
| 7   | 97  | Silanamine          | 1.303 | 58.1236 | 7.74  | 0.012   | 0.552                    |
| 8   | 423 | Alanine             | 1.361 | 123.0981| 37.89 | 0.000   | -0.875                   |
| 9   | 824 | Pentanedioic acid   | 1.528 | 198.0938| 24.56 | 0.006   | 0.237                    |
| 10  | 536 | L-Proline           | 1.375 | 143.0983| 17.43 | 0.000   | 0.628                    |
| 11  | 1079| L-Cysteine          | 1.434 | 248.1007| 24.55 | 0.031   | 0.262                    |
| 12  | 839 | Hexanoic acid       | 1.542 | 201.0984| 24.55 | 0.001   | 0.157                    |
| 13  | 1126| 1-Deoxyglucose      | 1.517 | 259.0339| 16.45 | 0.000   | 0.456                    |
| 14  | 586 | Pyridine            | 1.548 | 153.0160| 9.30  | 0.000   | 0.273                    |
| 15  | 1292| Silanol             | 1.341 | 302.1519| 24.55 | 0.013   | 0.120                    |
| 16  | 1390| Cyclohexasiloxane   | 1.993 | 329.1422| 37.86 | 0.000   | -0.402                   |
| 17  | 230 | Aspartic acid       | 1.348 | 84.0175 | 16.36 | 0.003   | 0.918                    |
| 18  | 169 | D-Galactose         | 1.751 | 73.1000 | 24.54 | 0.000   | 0.183                    |

ID: number of metabolite from the NIST library, VIP: Variable Importance in the Projection, RT: retention time. Fold change is calculated through the Logarithmic value (2 as the base value) of ratio between sea level group and high altitude group. Fold change with a positive value indicates a relatively higher concentration present in sea level group, whereas a negative value means a higher concentration in high altitude group. SL: sea level, HA: high altitude.
Table 3  
Significantly different metabolites between AMS group and non-AMS group (p < 0.05)

| No. | ID  | Metabolite         | VIP  | m/z      | RT  | P value | Log2 Fold change (AMS/non-AMS) |
|-----|-----|--------------------|------|----------|-----|---------|-------------------------------|
| 1   | 250 | Propanoic acid     | 3.428| 88.8809  | 9.69| 0.029   | 0.389                         |
| 2   | 1733| Silane             | 3.519| 438.1766 | 23.17| 0.025   | 0.452                         |
| 3   | 1121| Talose             | 3.031| 258.0762 | 23.16| 0.055   | 0.309                         |
| 4   | 746 | D-Glucose          | 3.328| 182.1373 | 31.88| 0.034   | 0.304                         |
| 5   | 1817| Uric acid          | 3.913| 480.4506 | 47.95| 0.012   | -0.378                        |
| 6   | 145 | 1-Deoxyglucose     | 3.081| 68.9991  | 23.17| 0.051   | 0.278                         |

Metabolic pathway analysis for differentially expressed metabolites

After searching the KEGG databases from the differential metabolites, we found 8 metabolomic pathways between AMS and non-AMS group and 27 pathways between sea level and high altitude group. The 18 differential metabolites between sea level group and high altitude status were found to be primarily involved in the aminoacyl-tRNA biosynthesis metabolism, cysteine and methionine metabolism, taurine and hypotaurine metabolism, thiamine metabolism, alanine, aspartate and glutamate metabolism, arginine and proline metabolism, pantothenate and CoA biosynthesis, nitrogen metabolism, galactose metabolism, nicotinate and nicotinamide metabolism, glycine, serine and threonine metabolism (Table 4). The 6 metabolites between AMS group and non-AMS group were found to be primarily involved in the glycolysis or gluconeogenesis metabolism, pentose phosphate pathway, propanoate metabolism, galactose metabolism, nicotinate and nicotinamide metabolism, starch and sucrose metabolism (Table 5).
| ID | Pathway Name                                      | Compound Name | KEGG ID |
|----|--------------------------------------------------|---------------|---------|
| 1  | Aminoacyl-tRNA biosynthesis                      | L-Tyrosine    | C00082  |
|    |                                                  | L-Cysteine    | C00097  |
|    |                                                  | L-Proline     | C00148  |
| 2  | Thiamine metabolism                             | Tyrosine      | C00082  |
|    |                                                  | L-Cysteine    | C00097  |
| 3  | Galactose metabolism                            | D-Glucose     | C00031  |
|    |                                                  | D-Galactose   | C00124  |
| 4  | Arginine and proline metabolism                 | Urea          | C00086  |
|    |                                                  | L-Proline     | C00148  |
| 5  | Amino sugar and nucleotide sugar metabolism     | D-Glucose     | C00031  |
|    |                                                  | D-Galactose   | C00124  |
| 6  | Cyanoamino acid metabolism                      | Alanine       | C01401  |
| 7  | Sulfur metabolism                               | L-Cysteine    | C00097  |
| 8  | Taurine and hypotaurine metabolism              | L-Cysteine    | C00097  |
| 9  | Alanine, aspartate and glutamate metabolism     | Aspartic acid | C00402  |
| 10 | Pantothenate and CoA biosynthesis               | L-Cysteine    | C00097  |
| 11 | Phenylalanine, tyrosine and tryptophan biosynthesis | Tyrosine    | C00082  |
| 12 | Glycolysis or Gluconeogenesis                    | D-Glucose     | C00031  |
| 13 | Pentose phosphate pathway                       | D-Glucose     | C00031  |
| 14 | Propanoate metabolism                           | Propanoic acid| C00163  |
| 15 | Ubiquinone and other terpenoid-quinone biosynthesis | Tyrosine    | C00082  |
| 16 | Glutathione metabolism                          | L-Cysteine    | C00097  |
| 17 | Nitrogen metabolism                             | Tyrosine      | C00082  |
| 18 | Nicotinate and nicotinamide metabolism          | Propanoic acid| C00163  |
| 19 | Phenylalanine metabolism                        | Tyrosine      | C00082  |
| 20 | Lysine degradation                              | Pentaenedioic acid | C00489 |
| 21 | Glycine, serine and threonine metabolism        | L-Cysteine    | C00097  |
Consequently, potential target metabolic pathway analysis with MetaboAnalyst revealed that metabolites, important for the host response to high altitude are the metabolism of aminoacyl-tRNA biosynthesis, cysteine and methionine, taurine and hypotaurine, thiamine, alanine, aspartate and glutamate, arginine and proline, pantothenate and CoA biosynthesis, nitrogen, galactose, nicotinate and nicotinamide, glycine, serine and threonine (Fig. 2A). Metabolism of glycolysis or gluconeogenesis, pentose phosphate, propanoate, galactose, nicotinate and nicotinamide, starch and sucrose were found to be distributed in the AMS group (Fig. 2B). Detailed related metabolic pathways were constructed using the reference map by searching KEGG (Fig. 3A and 3B).

The levels of key metabolites involved in the pathways of altered metabolites

To validate the levels of

**Discussion**
In our current study, we performed an integrated analysis of metabolomics profiling with the whole blood of individuals that exposed to high altitude hypoxia. Traveling to elevations above 3000 m is associated with the risk of developing AMS, HACE and HAPE. Among these complications, AMS is a severe and common disease that occurs after a rapid ascent to high altitude. Identification of molecular markers has the potential to improve the understanding of pathophysiological mechanisms and the diagnosis and prognosis of a condition, as well as to identify the most efficacious therapy. To date, clinical screening for AMS mainly relies on patient interviews, physician's examination and oxygen saturation tests. Specific tests or biomarkers, which would be more reliable and accessible for early diagnosis, are under urgent requirement. The large amount of data generated by omics research may be effective for the diagnosis of high altitude illnesses and may be used to improve our understanding of the pathogenesis of illnesses. Among these omics methods, metabolomics studies have enormous potential to identify potential biomarkers. Gas chromatograph-mass spectrometry (GC-MS), which harvests the information from various spectra of metabolites and facilitates rapid metabolite identification and quantification, proved to be a powerful platform for identifying biomarkers and understanding biochemical pathways to improve diagnosis, prognosis, and treatment of disease. Thus, in our current study, we performed GC-MS to investigate metabolic biomarkers associated with the pathophysiological response and susceptibility to high altitude hypoxia. Our results showed that the plasma metabolic profiles between the sea level and high altitude status were obviously different, while the separation was not that obvious between AMS group and non-AMS group. This indicates that the metabolic profile in the plasma of subjects ascending to high altitude and of AMS patients is altered.

Metabolic pathway analysis was conducted to further understand molecular function of these plasma metabolites. The metabolic pathways are discussed in detail below. In the metabolic profiles, glucose, the predominant energy sources in most organisms, decreased in AMS group, indicating a possible up-regulation of glycolysis. During high altitude acclimation, plasma lactate and pyruvate were increased more markedly in fed rats compared to fasted rats when rapidly exposed to an 8000 m altitude, which utilizes blood glucose as the substrate preferentially during hypoxia. In addition, glycolysis is correlated with an increased affinity of glucose receptors for deoxyglucose, stimulated by some growth factors and cytokines.

Uric acid, the end product of purine metabolism, is generated by the action of the enzyme XO, which catalyses the last two steps of uric acid conversion: hypoxanthine to xanthine and from xanthine to uric acid. The increased level of uric acid in AMS group is consistent with previous reports.

The levels of a wide variety of amino acids were altered by the pathogenesis of high altitude hypobaric hypoxia. Amino acid metabolism is so complex that a large number of metabolites were involved in the process. Chang Liu et al. also reported that AA metabolism pathway was one of the most pivotal alterations after acute hypoxia exposure and may account for variations in response patterns to hypoxia stimuli. The dysregulation of proteolysis, oxidative catabolism, and gluconeogenesis can lead to the metabolic disorder of amino acids. The decreased level of aspartic acid, a key metabolite in the pathway
of alanine, aspartate and glutamate metabolism was observed in high altitude group subjects. In addition, the level of alanine increased at high altitude, tyrosine and proline, two branched-chain amino acids, may be an important alternative energy substrate. It seems that the reduction in ATP production due to the inhibition of citrate cycle induced by the hypobaric hypoxia of high altitude could lead to the utilization of branched-chain amino acids as energy compensation. Branched-chain amino acids have been suggested as a useful supplementation in the treatment of lung disease and in trekking at high altitude.

The significantly decreased level of L-cysteine was also observed in high altitude group. Cysteine is known to increase the intracellular stores of glutathione thereby enhancing endogenous antioxidant levels. The effects of NAC are mainly generated through cysteine and glutathione. It has been reported that NAC supplemented rats showed less free radical production in comparison with hypoxic rats.

Luo et al. studied the metabolomic variation in the plasma of HAPE patients using 1H NMR and found that HAPE patients had significant several metabolites increased while some decreased in HAPE patients compared with the control group. According to his research, the HAPE patients had significant increase in valine, lysine, leucine, isoleucine, glycerol phosphoryl choline, glycine, glutamine, glutamic acid, creatinine, citrate, and methyl histidine and decrease in α- and β-glucose, trimethylamine, and the metabolic products of lipids.

In our current research, serum was collected from normal control volunteers before and after rapidly ascending to high altitude. In addition, a GC–MS-based metabolomics platform coupled with the machine learning method random forest models were successfully applied to explore the serum metabolic differences and changes of acute mountain sickness patients. The results showed that random forest models revealed characteristic and advantages on the discrimination between AMS and normal controls. Components that differed in levels between non-AMS group compared to AMS patients may serve as potential biomarkers for scanning acute mountain sickness at an early stage. To summarize, in AMS patients, aerobic metabolism is inhibited, whereas anaerobic glycolysis is increased. Changes in the levels of a number of related metabolites are obvious, but the specific regulatory sites and regulatory mechanisms that are involved and the biologic significance of such factors require further study.

**Conclusion**

Despite the limitation of sample size, this study illustrates the useful application of metabolomics analysis, based on GC–MS of blood plasma samples, for the investigation of metabolic changes in subjects rapidly ascending to high altitude and are susceptible to AMS. Moreover, this study suggests that metabolite analysis could provide a new understanding of AMS and may be useful for the pathophysiological mechanism investigation and in the diagnosis of AMS.

**Abbreviations**
AMS: acute mountain sickness,
HACE: high-altitude cerebral edema,
HAPE: high-altitude pulmonary edema,
GC-MS: gas chromatography-mass spectrometry,
NMR: Nuclear magnetic resonance,
LC-MS: liquid chromatography-mass spectrometry,
LLS: Lake Louise Score,
QC: quality control,
PCA: principal component analysis,
OPLS-DA: orthogonal partial least squares-discriminant analysis,
RT: Retention time,
MZ: Mass-to-charge ratio,
VIP: variable importance in the projection

**Declarations**

**Acknowledgements**

Not applicable.

**Ethics approval and consent to participate**

All experiments in this study were approved by the Ethical Committee of Chinese PLA General Hospital.

**Consent for publication**

Not applicable.

**Availability of data and materials**

Not applicable.
Funding

There is no funding for this manuscript.

Authors’ contributions

All authors conducted and contributed to the literature search. Chi Wang collected sample, analyzed data and prepared the manuscript, Hui Jiang and Jingwen Chen contribute to sample collection, Jinyan Duan contributes to the performance of GC-MS and data analysis. All authors read and approved the final manuscript.

Competing interests

The authors declare that there are no competing interests.

References

1. Luks AM, Swenson ER, Bartsch P. Acute high-altitude sickness. Eur Respir Rev. 2017;26(143).
2. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med. 2010;21(2):146-155.
3. Savourey G, Guinet A, Besnard Y, Garcia N, Hanniquet AM, Bittel J. Evaluation of the Lake Louise acute mountain sickness scoring system in a hypobaric chamber. Aviat Space Environ Med. 1995;66(10):963-967.
4. Kayser B, Aliverti A, Pellegrino R, et al. Comparison of a visual analogue scale and Lake Louise symptom scores for acute mountain sickness. High Alt Med Biol. 2010;11(1):69-72.
5. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26(1):51-78.
6. Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-1083.
7. Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int. 2014;34(9):1428-1444.
8. Simon-Manso Y, Lowenthal MS, Kilpatrick LE, et al. Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Anal Chem. 2013;85(24):11725-11731.
9. Lin Z, Vicente Goncalves CM, Dai L, et al. Exploring metabolic syndrome serum profiling based on gas chromatography mass spectrometry and random forest models. Anal Chim Acta. 2014;827:22-
10. Luo Y, Wang Y, Lu H, Gao Y. 'Ome' on the range: update on high-altitude acclimatization/adaptation and disease. *Mol Biosyst.* 2014;10(11):2748-2755.

11. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome. *Annu Rev Pharmacol Toxicol.* 2012;52:37-56.

12. Chen GZ, Qin J, Yu J, et al. Incidence of acute mountain sickness in young adults at 3200 meters: comparison of the Lake Louise Scoring and Chinese Scoring Systems. *Genet Mol Res.* 2013;12(4):6790-6801.

13. Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. *Analyst.* 2006;131(10):1075-1078.

14. Liao WT, Liu B, Chen J, et al. Metabolite Modulation in Human Plasma in the Early Phase of Acclimatization to Hypobaric Hypoxia. *Sci Rep.* 2016;6:22589.

15. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. *Wilderness Environ Med.* 2014;25(4 Suppl):S4-14.

16. Zhang L, Li M, Zhan L, et al. Plasma metabolomic profiling of patients with diabetes-associated cognitive decline. *PLoS One.* 2015;10(5):e0126952.

17. Pasikanti KK, Ho PC, Chan EC. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2008;871(2):202-211.

18. Yoshino M, Murakami K, Katsumata Y, Takabayashi A, Mori S. Stimulation of anaerobic metabolism in rats at high altitude hypoxia–adrenergic effects dependent on dietary states. *Comp Biochem Physiol B.* 1987;88(2):651-654.

19. Luo Y, Zhu J, Gao Y. Metabolomic analysis of the plasma of patients with high-altitude pulmonary edema (HAPE) using 1H NMR. *Mol Biosyst.* 2012;8(6):1783-1788.

20. Sinha S, Singh SN, Ray US. Total antioxidant status at high altitude in lowlanders and native highlanders: role of uric acid. *High Alt Med Biol.* 2009;10(3):269-274.

21. Tissot van Patot MC, Murray AJ, Beckey V, et al. Human placental metabolic adaptation to chronic hypoxia, high altitude: hypoxic preconditioning. *Am J Physiol Regul Integr Comp Physiol.* 2010;298(1):R166-172.

22. Liu C, Liu B, Liu L, et al. Arachidonic Acid Metabolism Pathway Is Not Only Dominant in Metabolic Modulation but Associated With Phenotypic Variation After Acute Hypoxia Exposure. *Front Physiol.* 2018;9:236.

23. Menier R, Talmud J, Laplaud D, Bernard MP. Branched-chain aminoacids and retraining of patients with chronic obstructive lung disease. *J Sports Med Phys Fitness.* 2001;41(4):500-504.

24. Shimizu M, Miyagawa K, Iwashita S, et al. Energy expenditure during 2-day trail walking in the mountains (2,857 m) and the effects of amino acid supplementation in older men and women. *Eur J*
25. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. *Eur J Clin Pharmacol.* 1989;36(2):127-131.

26. Jayalakshmi K, Singh SB, Kalpana B, Sairam M, Muthuraju S, Ilavazhagan G. N-acetyl cysteine supplementation prevents impairment of spatial working memory functions in rats following exposure to hypobaric hypoxia. *Physiol Behav.* 2007;92(4):643-650.

**Figures**

![Figure 1](image1)

**Figure 1**

PCA model and OPLS-DA model with corresponding values of R2X, R2Y and Q2 based on GC/MS data from sea level group and high altitude group. A. PCA score plot data of sea level groups (yellow) versus high altitude groups (green). B. OPLS-DA score plot data of sea level groups (yellow) versus high altitude groups (green). C, D. Validation plot obtained from permutation test, green triangle: R2; blue square: Q2. The green line represents the regression line for R2, and the blue line represents that for Q2.
Figure 1

PCA model and OPLS-DA model with corresponding values of R2X, R2Y and Q2 based on GC/MS data from sea level group and high altitude group. A. PCA score plot data of sea level groups (yellow) versus high altitude groups (green). B. OPLS-DA score plot data of sea level groups (yellow) versus high altitude groups (green). C, D. Validation plot obtained from permutation test, green triangle: R2; blue square: Q2. The green line represents the regression line for R2, and the blue line represents that for Q2.
The pathway impact of high altitude on plasma metabolites with MetaboAnalyst 3.0. A. Altered metabolic pathways between high altitude and sea level groups; a, aminoacyl-tRNA biosynthesis; b, cysteine and methionine metabolism; c, taurine and hypotaurine metabolism; d, thiamine metabolism; e, alanine, aspartate and glutamate metabolism; f, arginine and proline metabolism; g, pantothenate and CoA biosynthesis; h, nitrogen metabolism; i, galactose metabolism; j, nicotinate and nicotinamide metabolism; k, glycine, serine and threonine metabolism. B. Altered metabolic pathways between AMS group and non-AMS group; a, glycolysis or gluconeogenesis; b, pentose phosphate pathway; c, propanoate metabolism; d, galactose metabolism; e, nicotinate and nicotinamide metabolism; f, starch and sucrose metabolism.
The pathway impact of high altitude on plasma metabolites with MetaboAnalyst 3.0. A. Altered metabolic pathways between high altitude and sea level groups; a, aminoacyl-tRNA biosynthesis; b, cysteine and methionine metabolism; c, taurine and hypotaurine metabolism; d, thiamine metabolism; e, alanine, aspartate and glutamate metabolism; f, arginine and proline metabolism; g, pantothenate and CoA biosynthesis; h, nitrogen metabolism; i, galactose metabolism; j, nicotinate and nicotinamide metabolism; k, glycine, serine and threonine metabolism. B. Altered metabolic pathways between AMS group and non-AMS group; a, glycolysis or gluconeogenesis; b, pentose phosphate pathway; c, propanoate metabolism; d, galactose metabolism; e, nicotinate and nicotinamide metabolism; f, starch and sucrose metabolism.

**Figure 3**

Schematic overview of the metabolites and major metabolic pathway changes in plasma of the 36 subjects after arriving at high altitude. A. Metabolic pathway changes between individuals at sea level and at high altitude. B. Metabolic pathway changes between AMS group and non-AMS group. The metabolites are shown in color: red represents increased metabolites or enzymes; green represents decreased metabolites or enzymes and other white ones represent metabolites not changed in our experiment.
Figure 3

Schematic overview of the metabolites and major metabolic pathway changes in plasma of the 36 subjects after arriving at high altitude. A. Metabolic pathway changes between individuals at sea level and at high altitude. B. Metabolic pathway changes between AMS group and non-AMS group. The metabolites are shown in color: red represents increased metabolites or enzymes; green represents decreased metabolites or enzymes and other white ones represent metabolites not changed in our experiment.